Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

eloping novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia® for rheumatoid arthritis and Crohn's Disease, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect the company's current views regarding the scientific and commercial potential of NKTR-118, the results of the Phase 2 study for that drug candidate and the potential of the company's product development pipeline and technology platform. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) NKTR-118 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage prior to regulatory approval due to efficacy, safety or other factors; (ii) the timing or success of the commencement or end of clinical trials and comme
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
(Date:7/10/2014)... been extremely challenging because there are many genetic variants ... disease. Now investigators reporting in the July 3rd issue ... describe a strategy that may help reveal how ... or environmental exposures to affect the development of the ... may predispose individuals to schizophrenia. , The work ...
(Date:7/10/2014)... lithium-ion batteries that power our laptops and electric vehicles ... single charge with the help of a sponge-like silicon ... replace the graphite traditionally used in one of the ... the energy storage capacity of graphite. A paper describing ... published today in Nature Communications . , "Silicon ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... adison, Wis. - Third Wave Technologies, Inc. ... a share, for the second quarter of 2006, but robust ... upward in a key market. , ,Third Wave, which develops ... that revenue rose by 15 percent for the quarter ended ...
... Madison, Wis. - A United States Air Force contract ... not only provide a Madison aerospace research and product development ... it to propel something much larger. , ,The U.S. ... Orbital Technologies Corp. (Orbitec) for the development of ...
... - Thanks to a classified contract from the ... company headquartered here, reported record revenues and earnings for ... the closing of its manufacturing facility in England. , ... of lower-than-expected earnings in the fourth quarter, which caused ...
Cached Biology Technology:Third Wave reports another loss, stronger sales 2Third Wave reports another loss, stronger sales 3Orbitec will use $25 million Air Force contract to make small launch vehicle 2Defense contract helps Plexus gain record profits 2
(Date:7/11/2014)... the Department of Energy,s Oak Ridge National Laboratory ... R&D Magazine in recognition of the year,s top ... tremendous value of our National Labs," said Secretary ... the National Labs continues to help our nation ... and technological innovations necessary to remain globally competitive." ...
(Date:7/11/2014)... The University of Chicago is creating a new ... at the University,s Institute for Molecular Engineering and ... million donation from the Millicent and Eugene Bell ... will reside within the Institute for Molecular Engineering. ... research project at the MBL,s Eugene Bell Center ...
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2
... the University of Leeds are developing methods of helping ... chemicals such as vinegar. , The harmful chromium ... from former textiles factories, smelters, and tanneries have been ... problems with the kidneys, liver, lungs and skin. , ...
... but researchers in China have discovered that chicken manure can ... in the International Journal of Environment and Pollution ... 50% more crude oil than soil lacking the guano. ... University, China, point out that contamination of soil by crude ...
... comes to solving complex problems, Geoffrey von Maltzahn, MIT ... solutions. Finding inspiration in systems that evolution has produced, ... society,s biggest challenges: improving tumor detection and therapeutic delivery ... patients. Today, the 28-year-old Ph.D. candidate in ...
Cached Biology News:Cleansing toxic waste -- with vinegar 2Fowl soil additive breaks down crude oil 2MIT student develops new innovations to selectively kill cancer cells 2MIT student develops new innovations to selectively kill cancer cells 3MIT student develops new innovations to selectively kill cancer cells 4
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
COMING SOON: Anti-Mouse C5/C5b, Clone BB5.1. Monoclonal Antibody...
KAI 1 (G-2)...
Biology Products: